It is also being examined in a clinical trial in combination with the MEK-162 inhibitor for patients with advanced CRC, esophageal, pancreatic, NSCLC or other advanced solid tumors containing RAS or BRAF mutations (NCT01449058). This evidence concerns the gene MAP2K7 and colorectal carcinoma.